Ab Science Paris (ABSCF) 16.8900 $ABSCF
AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting
GlobeNewswire - Mon May 18, 11:43AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that the three abstracts reporting on phase 2 studies of masitinib in metastatic colorectal cancer, metastatic esophagogastric adenocarcinoma, and advanced triple negative breast cancer, will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 - June 2 in Chicago, Illinois, US).
AB: 31.19 (+0.44)
AB Science: Masitinib Treatment of Advanced Pancreatic Cancer, publication of Phase III Results in Annals of Oncology
GlobeNewswire - Thu Apr 09, 11:25AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first randomized phase 3 study of masitinib in treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Entitled, 'A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer' this article and its accompanying Online Supplementary Material are freely accessible online from the peer-reviewed journal Annals of Oncology: http://annonc.oxfordjournals.org/lookup/doi/1...onc/mdv133. A phase 3 confirmatory study is currently ongoing.
AB: 31.19 (+0.44), LLY: 72.94 (+0.04)
AB Science: Masitinib Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis from FDA
GlobeNewswire - Fri Mar 20, 1:32PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 31.19 (+0.44)
AB Science: Positive Phase 2 Clinical Study Data of Masitinib in Second-Line Metastatic Stomach Cancer
GlobeNewswire - Mon Feb 02, 11:26AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced encouraging efficacy and safety results from a phase 2 study with its investigational drug, masitinib, in patients with nonresectable, metastatic esophagogastric adenocarcinoma after progression to first-line treatment.
AB: 31.19 (+0.44)
AB Science: The Data and Safety Monitoring Board Recommends the Continuation of Phase 3 Study of Masitinib in Amyotrophic Lateral Sclerosis
GlobeNewswire - Tue Jan 13, 10:48AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) based upon review of the latest safety data. The DSMB was created as part of the Company's pivotal clinical study evaluating masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 31.19 (+0.44)
AB Science advances Ultra-Selective SYK Kinase Inhibitor into Full Preclinical Development
GlobeNewswire - Fri Nov 28, 10:58AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), reported the advancement of a novel, small molecule SYK kinase inhibitor named AB8779 into full preclinical development.
AB: 31.19 (+0.44)
AB Science: Web conference on masitinib in asthma - Safety and Efficacy Update
GlobeNewswire - Tue Nov 25, 10:55AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of asthma with key opinion leaders from this disease.
AB: 31.19 (+0.44)
AB Science: The Data and Safety Monitoring Board recommends the continuation of the phase 2 study with masitinib in advanced hepatocellular carcinoma
GlobeNewswire - Wed Nov 12, 10:50AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 2 study of masitinib in advanced hepatocellular carcinoma based upon review of the latest safety and efficacy data. The DSMB was created as part of the Company's clinical study evaluating masitinib in the treatment of advanced hepatocellular carcinoma.
AB: 31.19 (+0.44)
AB Science : Web conference on Masitinib in mastocytosis
GlobeNewswire - Fri Oct 31, 11:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of mastocytosis with key opinion leaders from this disease.
AB: 31.19 (+0.44)
AB Science: publication of preclinical data on the neuroprotective effect of masitinib
GlobeNewswire - Thu Oct 30, 12:13PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of preclinical study results with masitinib in ischemic stroke. Entitled, 'Neuroprotective effect of masitinib in rats with postischemic stroke' this article and its accompanying supplementary information are freely accessible online from the peer-reviewed journal Naunyn-Schmiedeberg's Archives of Pharmacology: http://link.springer.com/article/10.1007%2Fs00210-014-1061-6
AB: 31.19 (+0.44)
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
BIIB: 395.42 (+4.18), VRTX: 127.31 (+1.10), PFE: 33.98 (-0.01), INCY: 107.65 (+0.79), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), RIGL: 4.05 (-0.04), NVO: 56.92 (+0.17), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), ABBV: 65.61 (-0.38), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting
GlobeNewswire - Mon May 18, 11:43AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that the three abstracts reporting on phase 2 studies of masitinib in metastatic colorectal cancer, metastatic esophagogastric adenocarcinoma, and advanced triple negative breast cancer, will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 - June 2 in Chicago, Illinois, US).
AB: 31.19 (+0.44)
AB Science: Masitinib Treatment of Advanced Pancreatic Cancer, publication of Phase III Results in Annals of Oncology
GlobeNewswire - Thu Apr 09, 11:25AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first randomized phase 3 study of masitinib in treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Entitled, 'A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer' this article and its accompanying Online Supplementary Material are freely accessible online from the peer-reviewed journal Annals of Oncology: http://annonc.oxfordjournals.org/lookup/doi/1...onc/mdv133. A phase 3 confirmatory study is currently ongoing.
AB: 31.19 (+0.44), LLY: 72.94 (+0.04)
AB Science: Masitinib Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis from FDA
GlobeNewswire - Fri Mar 20, 1:32PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 31.19 (+0.44)
AB Science: Positive Phase 2 Clinical Study Data of Masitinib in Second-Line Metastatic Stomach Cancer
GlobeNewswire - Mon Feb 02, 11:26AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced encouraging efficacy and safety results from a phase 2 study with its investigational drug, masitinib, in patients with nonresectable, metastatic esophagogastric adenocarcinoma after progression to first-line treatment.
AB: 31.19 (+0.44)
AB Science: The Data and Safety Monitoring Board Recommends the Continuation of Phase 3 Study of Masitinib in Amyotrophic Lateral Sclerosis
GlobeNewswire - Tue Jan 13, 10:48AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) based upon review of the latest safety data. The DSMB was created as part of the Company's pivotal clinical study evaluating masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 31.19 (+0.44)
AB Science advances Ultra-Selective SYK Kinase Inhibitor into Full Preclinical Development
GlobeNewswire - Fri Nov 28, 10:58AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), reported the advancement of a novel, small molecule SYK kinase inhibitor named AB8779 into full preclinical development.
AB: 31.19 (+0.44)
AB Science: Web conference on masitinib in asthma - Safety and Efficacy Update
GlobeNewswire - Tue Nov 25, 10:55AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of asthma with key opinion leaders from this disease.
AB: 31.19 (+0.44)
AB Science: The Data and Safety Monitoring Board recommends the continuation of the phase 2 study with masitinib in advanced hepatocellular carcinoma
GlobeNewswire - Wed Nov 12, 10:50AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 2 study of masitinib in advanced hepatocellular carcinoma based upon review of the latest safety and efficacy data. The DSMB was created as part of the Company's clinical study evaluating masitinib in the treatment of advanced hepatocellular carcinoma.
AB: 31.19 (+0.44)
AB Science : Web conference on Masitinib in mastocytosis
GlobeNewswire - Fri Oct 31, 11:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of mastocytosis with key opinion leaders from this disease.
AB: 31.19 (+0.44)
AB Science: publication of preclinical data on the neuroprotective effect of masitinib
GlobeNewswire - Thu Oct 30, 12:13PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of preclinical study results with masitinib in ischemic stroke. Entitled, 'Neuroprotective effect of masitinib in rats with postischemic stroke' this article and its accompanying supplementary information are freely accessible online from the peer-reviewed journal Naunyn-Schmiedeberg's Archives of Pharmacology: http://link.springer.com/article/10.1007%2Fs00210-014-1061-6
AB: 31.19 (+0.44)
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
BIIB: 395.42 (+4.18), VRTX: 127.31 (+1.10), PFE: 33.98 (-0.01), INCY: 107.65 (+0.79), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), RIGL: 4.05 (-0.04), NVO: 56.92 (+0.17), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), ABBV: 65.61 (-0.38), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
